Abstract-The analgesic action of the enkephalin analog EK-399 (Tyr-D-Met(O) Gly-EtPhe-NHNHCOCH3•AcOH) and the subtypes of the opiate receptors mediating the action were studied.
The discovery of enkephalins, endogenous morphine-like peptides, has encouraged the search for synthetic enkephalin analogs with potent analgesic activity without dependence (1) . Fujino et al. (2) synthesized acylhy drazide enkephalin analogs consisting of 4 amino acids with potent analgesic activities. The receptor binding assay in the rat brain homogenate and experiments on the de pendence liability of our previous study in dicated that some of these analogs would not necessarily interact with only /t-receptors (3, 4). In the present study, we examined the analgesic action of the acylhydrazide enke phalin analog Tyr-D-Met(O)-Gly-EtPhe NHNH000H3-AcOH (EK-399), which was designed and synthesized by Dr. Fujino et al.
(to be reported elsewhere), and experiments were carried out to study the opiate receptor subtypes mediating the analgesic action of EK-399.
Materials and Methods
Analgesia: Male Jcl:SD, 6 week-old rats were used. Analgesia was measured by the tail-flick and the hot-plate tests. Tail-flick  latencies were measured by an analgesia meter (IITC, MOD 33), adjusting the response time to between 6 and 8 sec in the pre-drug controls. The cut-off time was 15 sec. In the hot plate test, the rat was placed on a copper surface surrounded by a plexiglass wall with diameter of 15 cm and a height of 21 cm. The temperature of the surface was maintained at 55.0±0.5°C.
The measured end point of the hot plate was when the rat licked its hind paw or jumped. by an intraperitoneal in jection of 50 mg/kg pentobarbital-Na.
A polyethylene tube (PE-10) was inserted into the spinal subarachnoid space 8 cm down from cisterna magna, and the other end of the tube was affixed to the skull by dental cement (Yata Polyset). The animals were used 5-7 days after the surgical procedures.
By a microsyringe, the drugs, dissolved in saline, were injected in a volume of 5 /l followed by 5 ,cl of saline to flush the cannula.
Chronic tolerance: Male Jcl:SD, 6 week old rats were used. Morphine (20 mg/kg, s.c.) was injected twice daily at 9 a .m. and 5 p.m. for 8 consecutive days. Analgesia was measured by the tail flick test on the morning of the 9th day. EK-399 (0.5 mg/kg, s.c.) was injected once daily at 9 a.m. for 4 days. Analgesia was measured on the morning of the 5th day.
Opiate receptor binding assay: The method used was the same as that described pre viously (4). In principle, the brains minus cerebella, from 6 week old male rats, were homogenized in 30 volumes (w/v) of 50 mM Tris-HCI buffer and centrifuged for 10 min at 40,000 x g. The pellets were resuspended i n 30 volumes of Tris-buffer and incubated for 30 min at 37'C. The homogenate was recen trifuged for 10 min at 40,000 x g, and the pellets were suspended in ice-cold Tris buffer equal to the original volume. Aliquots of the homogenate containing 1 nM 3H-Met-enke phalin were incubated in triplicate with or without 10 /iM of cold Met-enkephalin in the presence of 50 ug/ml of bacitracin for 3 hr at 0°C. When studying the 3H-naloxone binding assay, aliquots of the homogenates containing 2 nM 3H-naloxone were incubated with 1 ,cM levallorphan or 1 ;cM dextral lorphan in the presence of bacitracin (50 /cg/ ml). Immediately after the incubation, the samples were filtered by glass filters (What man GF/B) under a vacuum. The filters were washed with two 5 ml portions of ice-cold Tris-buffer. The specific binding was defined as the difference between the binding of the labeled ligands in the presence and absence of the excess cold ligands. IC50s, the con centrations that inhibit the specific binding by 50%, were obtained from a log-probit graph.
Drugs 
Results
Analgesic activity: The time course of the analgesic activity of morphine and EK-399 in the tail flick test is shown in Fig. 1 . The analgesic effect of morphine was maximum at 30 or 45 min after it was administered subcutaneously and decreased with time. On the other hand, the effect of EK-399 was maximum as late as 2 hr after it was adminis tered, and the duration of action was long lasting; its effect was clearly evident 5 hr after it was administered. The ED50 value of EK-399 was just one tenth that of morphine ( Table 1 ). The analgesic effect of EK-399 was more potent and of longer duration than that of morphine.
The spinal cord is one of the most important sites of action for opiates (6). In this experi ment, the analgesia induced by intrathecal injection was assayed by the hot plate test. The results of the experiment are shown in Fig. 2 .
The time course of the analgesic effect of EK-399 and morphine were almost the same. Their effects peaked at 45 min after the injections and then were gradually attenuated. However, EK-399 was about 800 (about 1800 in molar ratio) times as potent as morphine (Table 1 ) .
Receptor assay: In this experiment, 3H naloxone and 3H-Met-enkephalin were used Each bar represents the meant S.E. mM Na. EK-399 also had a high affinity for 6 receptors, which was comparable to that of (3-endorphin. To evaluate the relative prefer ence for /c or a'-receptors, the ratio of the IC50 for 3H-naloxone to that for 3H-Met enkephalin is useful. The ratio for morphine is 11, indicating a high preference for /t receptors. On the other hand, the ratio of Met enkephalin is 0.32, indicating a high r) receptor selectivity. The ratio of EK-399 is 5.9, intermediate between morphine and Met enkephalin.
Naloxone antagonism:
The apparent pA2 values with naloxone by the Schild plot (7) were determined to obtain information on the receptor subtypes on which EK-399 and morphine act on in vivo. The tail flick test was performed at 45 and 90 min after the subcu taneous injections of morphine and EK-399, respectively. The peak effect time of subcu taneously injected naloxone was 20-30 min after the administration in a preliminary ex periment, so it was injected 25-30 min before the analgesic measurements so as to meet the peak effect times of each drug.
The apparent pA2 value for morphine naloxone was 7.65 (7.52-7.82) and that for EK-399-naloxone was 5.93 (5.85-6.06); the difference was significant. Both pA2 plots gave straight lines. The slopes for morphine and for EK-399 were -1.03 (-0.90--1.16) and -1.15 (-0.96--1.34), respectively. Both are quite close to the theoretical value of -1 .0 (Fig. 3) .
Cross tolerance between morphine and EK-399: The ED50 values of morphine and EK-399 by the rat tail flick test were increased by 2.7 and 6.1 times after the chronic admin istration of morphine and EK-399, respectively (Table 3 ). The ED50 values of morphine for the EK-399 tolerant rats was 4.4 times higher than for the naive animals, while the ED50 value of EK-399 for the morphine tolerant rats was not appreciably different from that for the naive rats. These results indicate that EK-399 tolerant rats had a tolerance to morphine, but morphine tolerant rats had no tolerance to EK-399; that is, one way cross tolerance was observed between morphine and EK-399. on smooth muscle pre parations in vitro or receptor binding in brain homogenates (9-11 ). The /t-receptor for morphine, the ic-receptor for ethylketocy clazocine and the s-receptor for enkephalins are thought to be of the main subtype opiate receptors involved in the mechanisms of analgesia production.
EK-399 had a potent antinociceptive activity against the thermal nociceptive stimuli applied to the tail, and the pA2 value of naloxone-EK-399 was signifi cantly lower than that of naloxone-morphine. It is well-known that lc-agonists, including ethyl ketocyclazocine, have only weak analge sia against thermal nociceptive stimuli (12 14). The possibility that the ic-receptors con tribute mainly to the antinociceptive effect of EK-399 in the present experiments may be low.
as the ligands for the It and 6-receptors, re spectively. The IC50 ratio for 3H-naloxone to 3H-Met-enkephalin is a good index for the preference to the receptor population. The ratio of morphine was 11 and that of Met enkephalin was 0.32, which clearly indicates the specificity for ii and 6, respectively. On the other hand, the ratio of EK-399 was 5.9. With respect to receptor subtype selectivity, EK-399 is different from both morphine and Met-enkephalin. The sodium-response ratios are thought to be a useful index for predicting the narcotic antagonistic property (15). The sodium response ratio of EK-399 was 1.2, com parable to that of the opiate antagonist levallorphan.
Some enkephalin analogues have relatively low sodium response ratios in spite of their lack of definite antagonistic activities (16). Thus the sodium response ratios do not necessarily reflect the antago nistic properties.
However, we have con firmed that EK-399, in a limited dose range, partially reversed the analgesic action of morphine in mice by the tail pinch method S. Kuzuna et al., unpublished data). There is a possibility that EK-399 may have partial antagonistic activities under limited experi mental conditions.
To analyze the receptor population in volved in the analgesic action of EK-399 in vivo, we performed the Schild analysis (17, 18) and the cross tolerance test between EK 399 and morphine. The antagonistic effect of naloxone against EK-399 was very weak, as shown by a low value of pA2 compared with that for morphine. The following three pos sibilities may explain the two different pA2 values of naloxone: 1) The analgesic receptor subtypes for EK-399 were different from that for morphine. 2) The drug-receptor equili brium was not attained. 3) Morphine and EK 399 interact on the same kind of receptors, but their binding mode are different. Although the experiments in vivo may give only indirect pharmacologic analysis mainly because of the difficulties in controlling the drug con centration or in attaining equilibrium con ditions, it gives additional information about the opiate receptor population involved in the analgesic action of EK-399. In this experi ment, we paid attention to getting the equilibrium of the interaction between the drugs and receptors by matching the peak effect times of the drugs. In some cases, the lack of equilibrium does not markedly affect the pA2 value analysis in experiments in vivo (17). It seems difficult to explain the results of the present pA2 analysis by the second pos sibility.
The slopes of the Schild plot for morphine naloxone and EK-399-naloxone closely ap proximate the theoretical value of 1, sug gesting that these drugs should interact with opiate receptors according to the Langmuir equation. Therefore, the third possibility could be excluded.
Since the first seems to be most probable, it is conceivable that EK-399 and morphine interact with different kinds of opiate receptor subtypes.
The one way cross tolerance between morphine and EK-399 presents another in teresting additional piece of information about the analgesic receptor subtype of EK-399. EK-399 tolerant rats had a tolerance to mor phine, suggesting the involvement of it receptors in the analgesic action of EK-399. On the other hand, morphine tolerant rats did not show tolerance to EK-399, just like DADL, a s-agonist of an enkephalin analog (19). The result of pA2 analysis also supports this possibility. Taken together, the present data indicate that EK-399 may exert its analgesic effect at least via /i and 6-receptors.
Yaksh et al. (20) and Schmauss and Yaksh (12) reported that i.t. injected (3-endorphin and metkephamid, both of which have high affinities to /c and 6-receptors, showed potent analgesia, especially against thermal nociceptive stimuli. The authors suggest that the coactivation of it and s-receptors results in synergism in the spinal cord. This kind of synergism contribute to the potent analgesic effect of intrathecally injected EK-399 against thermal nociceptive stimuli.
